Prelude Therapeutics Refocuses Strategy to Advance Key Cancer Programs

Prelude Therapeutics streamlines its oncology pipeline — prioritizing JAK2V617F and KAT6A programs, pausing SMARCA2, and securing major funding through an Incyte partnership.